Full-Time

Clinical Study Specialist

Posted on 3/20/2025

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops biopharmaceuticals for serious diseases

Compensation Overview

$92.5k - $151.1k/yr

Junior, Mid

Westchester County, NY, USA + 1 more

More locations: Berkeley Heights, NJ, USA

This role is hybrid and requires 3 days in-office work per week.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Data Analysis
Google Cloud Platform
Excel/Numbers/Sheets
Requirements
  • Attention to details for the ability to track information and deliver on assigned study activities
  • Good communication and interpersonal skills; ability to build relationships internally and externally
  • Ability to be resourceful and to demonstrate problem solving skills
  • Demonstrate the ability to proactively assess information and investigate impact on clinical trials
  • Ability to acquire working knowledge in trial management systems and MS applications including (but not limited to) Project, PowerPoint, Word, Excel, IVRS/IWRS, EDC, TMF
  • Proactive and self-disciplined, ability to meet deadlines, effective use of time, and prioritization
  • Basic familiarity with medical terms and clinical drug development
  • Awareness of ICH/GCP
  • Bachelor’s degree with 2+ years of relevant experience or Associates Degree with 5+ years of relevant experience.
Responsibilities
  • Organizes and delivers analyzable reports and metrics to the clinical study lead
  • Schedules and coordinates meetings, prepares agendas, presentation materials and minutes for clinical study team meetings and other study related meetings
  • Collates data for assessments such as feasibility and site selection and reviews site usability database
  • Contributes to review of study documents such as informed consent forms, case report forms and facilitates study document reviews per company standard operating procedures
  • Compiles study manuals including but not limited to: study reference binders and manuals and maintains versioning of study reference materials (e.g., regulatory, pharmacy, and laboratory binders)
  • Collates materials for training and investigator meetings
  • Tracks site activation, enrolment and monitoring visits to projected plans, and escalate any issues or delays with site activation or deviations from monitoring plan
  • Monitors and updates investigator/site status for the trial, and supports with clinical trial registry postings
  • Performs scheduled reconciliations of study Trial Master File (TMF) with clinical study lead guidance
  • Ensures scheduled reports are received (i.e. 1572 reportable changes, financial disclosure form)
  • Manages and maintains team SharePoint and/or shared drive sites, as needed
  • Communication with sites as directed and maintains site contact information
  • Contributes to line listings review for Blind Data Review Meeting (BDRM)
  • May manage or contribute to oversight of Third Party Vendors (TPV)
  • Tracks and monitors close out activities – study close-out documents (1572s, Investigational Product reconciliation, Financial Disclosures, etc.) and CRA close-out visits
  • Participates in Standard Operating Procedures (SOPs) revisions or departmental initiatives
  • Proactively recommends process improvement initiatives for the department
  • May require 25% travel
Desired Qualifications
  • Proactive and self-disciplined, ability to meet deadlines, effective use of time, and prioritization
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often working with academic institutions and other pharmaceutical companies to enhance its efforts. Regeneron generates revenue by selling its approved medicines and through partnerships that involve sharing development costs and profits. Unlike many competitors, Regeneron focuses heavily on collaboration and has a strong emphasis on research and development. The goal of Regeneron is to improve patient outcomes by providing effective treatments for serious health issues.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Regeneron's Dupixent shows promise in treating bullous pemphigoid with positive trial results.
  • Increased investments in AI-driven drug discovery could boost Regeneron's R&D capabilities.
  • The rise of personalized medicine aligns with Regeneron's focus on targeted therapies.

What critics are saying

  • Regeneron faces competition from companies like Amgen and AstraZeneca in similar therapeutic areas.
  • Potential regulatory delays, as seen with odronextamab, could impact market timelines.
  • Adverse events in new treatments like Dupixent may affect patient safety perceptions.

What makes Regeneron Pharmaceuticals unique

  • Regeneron excels in developing life-transforming medicines for serious diseases.
  • The company leverages proprietary technologies for innovative drug discovery and development.
  • Strategic partnerships enhance Regeneron's research and development capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PR Newswire
Mar 11th, 2025
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million To High School Seniors For Innovative Research On Classifying Celestial Objects, Treating A Rare Muscle Disease And Solving A Long-Standing Math Problem

$250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competitionTARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Matteo Paz, 18, of Pasadena, California, won the top award of $250,000 in the 2025 Regeneron Science Talent Search, the U.S.'s oldest and most prestigious science and math competition for high school seniors.Congratulations to the top three Regeneron Science Talent Search award winners, Ava Grace Cummings, Matteo Paz and Owen Jianwen Zhang (left to right) Photo Credit: Chris Ayers Photography/Licensed by Society for ScienceNow in its 84th year, the competition celebrates and rewards young innovators who are applying their Science, Technology, Engineering and Math (STEM) talent and leadership skills to push the boundaries of discovery and address today's pressing challenges.Forty finalists, including Matteo, were honored this evening during an award ceremony at the National Building Museum in Washington, D.C, where they were awarded more than $1.8 million in prizes for their groundbreaking research, exceptional problem-solving skills and potential to shape the future of STEM.Matteo Paz , 18, of Pasadena, California , won first place and $250,000 for designing machine-learning algorithms to efficiently comb through 200 billion entries of raw NEOWISE infrared full-sky data. By analyzing tiny changes in infrared radiation, the AI sorted the objects into 10 classes. He found 1.5 million new potential objects.won first place and for designing machine-learning algorithms to efficiently comb through 200 billion entries of raw NEOWISE infrared full-sky data. By analyzing tiny changes in infrared radiation, the AI sorted the objects into 10 classes

PharmiWeb
Mar 10th, 2025
Dupixent Late-Breaking Positive Pivotal Data In Bullous Pemphigoid Presented At Aad

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itchDupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the US and the EUParis and Tarrytown, NY, March 8, 2025. Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting. BP is a chronic, debilitating, and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin, and painful lesions.Victoria Werth, MDChief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Professor of Dermatology and Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, and principal investigator of the study“People with bullous pemphigoid live with unrelenting itch, blisters, and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can be challenging for this primarily elderly patient population because they work by suppressing their immune system. By targeting the underlying type 2 inflammation, which is a key driver for bullous pemphigoid, Dupixent is the first investigational biologic to show sustained disease remission and reduce disease severity and itch compared to placebo in a clinical study.”The ADEPT study met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg (n=53) every two weeks after an initial loading dose or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained

MarketBeat
Mar 10th, 2025
American Assets Inc. Makes New $427,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

American Assets Inc. makes new $427,000 investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

PR Newswire
Mar 1st, 2025
Positive Results From Tezspire® (Tezepelumab-Ekko) Phase 3 Waypoint Trial Highlight Rapid, Sustained Effect In Chronic Rhinosinusitis With Nasal Polyps

Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery. Data Published in NEJM and Presented at AAAAI/WAO 2025. THOUSAND OAKS, Calif., March 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for surgery and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) compared to placebo.1,2 The data were published today in the New England Journal of Medicine and were highlighted as a late-breaking oral presentation during the American Academy of Allergy Asthma Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego.1,2

RegMedNet
Feb 27th, 2025
Cell therapy weekly: world's first hospital-based autologous foundry

At the Research in Otolaryngology's 48th Annual MidWinter Meeting (22 - 26 February 2025; Orlando, FL), Regeneron Pharmaceuticals provided an update on the Phase I/II CHORD trial for DB-OTO, an investigational gene therapy for congenital hearing loss due to OTOF gene variants.